 This study is 1 of 4 clinical trials currently conducted as part of the WHO-led VEBCON consortium, aiming to generate harmonized data for the rVSVΔG-ZEBOV-GP BPSC1001 vaccine candidate to allow optimized rapid decisions on dose and safety. 